#jpmorganhealthcareconference — Public Fediverse posts

D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100288

D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100288

D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100288

D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100288

Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079

Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079

Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079

Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079

Moderna shares have surged over 20% year-to-date, driven by optimism for its personalized cancer vaccine and anticipation ahead of the JP Morgan Healthcare Conference, though analysts warn of high risks and potential retracement if key catalysts do not materialize.
#YonhapInfomax
#Moderna #CancerVaccine #SharePrice #JPmorganHealthcareConference #ClinicalData
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98935

Moderna shares have surged over 20% year-to-date, driven by optimism for its personalized cancer vaccine and anticipation ahead of the JP Morgan Healthcare Conference, though analysts warn of high risks and potential retracement if key catalysts do not materialize.
#YonhapInfomax
#Moderna #CancerVaccine #SharePrice #JPmorganHealthcareConference #ClinicalData
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98935

Moderna shares have surged over 20% year-to-date, driven by optimism for its personalized cancer vaccine and anticipation ahead of the JP Morgan Healthcare Conference, though analysts warn of high risks and potential retracement if key catalysts do not materialize.
#YonhapInfomax
#Moderna #CancerVaccine #SharePrice #JPmorganHealthcareConference #ClinicalData
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98935

Moderna shares have surged over 20% year-to-date, driven by optimism for its personalized cancer vaccine and anticipation ahead of the JP Morgan Healthcare Conference, though analysts warn of high risks and potential retracement if key catalysts do not materialize.
#YonhapInfomax
#Moderna #CancerVaccine #SharePrice #JPmorganHealthcareConference #ClinicalData
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98935

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750